Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal fentanyl for breakthrough cancer pain
2005-002347-82Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breakthrough pain and cancer pain comparing Intranasal fentanyl with Placebo (2 arms). Primary endpoint: Pain Intensity Difference at 10 minutes (PID10). Started Feb 2006; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough paincancer pain
Beyond the preview
Go deeper on 2005-002347-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002347-82.